CV Therapeutics Wins FDA Approval

CV Therapeutics (CVTX NASDAQ) and Astellas Pharma Inc announced on Friday that the U.S. Food and Drug Administration has approved Lexiscan (regadenoson), a heart imaging agent.

Astellas signed a license agreement with CV Therapeutics for the development and sale of the agent in July 2007.

CV Therapeutics, Astellas Heart-Monitor Drug Approved

stem and leaf plot maker